Source facts
FDA issued an approval letter for SOLIQUA 100/33 on 2026-03-16. The source metadata identifies BLA 208673 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
SOLIQUA 100/33 — FDA Approval Letter (BLA 208673)
Issued to SANOFI-AVENTIS US. Application is approved as submitted.
Issued
March 16, 2026Application
BLA • 208673
Product
SOLIQUA 100/33
Company
SANOFI-AVENTIS US
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for SOLIQUA 100/33?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: BLA 208673.
- 3Submission: supplement.
- 4Sponsor: SANOFI-AVENTIS US.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the SOLIQUA 100/33 approval letter
Is SOLIQUA 100/33 FDA approved?
This letter documents an FDA approval action: FDA approved BLA 208673 for SOLIQUA 100/33, sponsored by SANOFI-AVENTIS US, on March 16, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is BLA 208673?
BLA 208673 is the application under which FDA issued this approval letter for SOLIQUA 100/33 to SANOFI-AVENTIS US. The letter is dated March 16, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.